Development of Therapies for Celiac Disease  March 20-21, 2014 



Host Celiac Disease Center at Columbia University, New York

A scientific program designed for those interested in the development of non-dietary therapies for celiac disease. Speakers are listed below.  

Some information was embargoed because of upcoming publication of data.
  • Introduction  Peter Green, MD
    • Immune pathogenesis of celiac disease  Ludwig Sollid - Norway
        Read more by clicking on each section below.
  • The immune response to wheat proteins  Paul Ciclitira - UK (Moderator)
  • Nutritional quality of seed storage proteins Joachim Messing - USA 
  • Wheat gluten and celiac disease - an evolutionary collision  Donald Kasarda – USA
  • Immune response to glutenin and other grains in celiac disease  Paul Ciclitira - UK 
  •  Wheat amylase-trypsin inhibitors: their role in celiac disease and beyond. Detlef Schuppan - Germany 
  • Immune response to non gluten proteins  Armin Alaedini, PhD -- USA 
  • Q&A

  • Celiac disease and refractory celiac disease   Govind Bhagat - USA (Moderator)
  • Neglected intraepithelial innate lymphocytes in celiac disease pathogenesis Govind Bhagat - USA
  • The dark side of the moon : managing refractory celiac disease Joseph Murray - USA
  • Discovery and development of a new anti IL-15 antibody for type II refractory celiac disease therapy Alain Vicari - Switzerland
  • Toleragenic immune modifying nanoparticles for the treatment of celiac disease Daniel Getts - USA

  • Epidemiological factors    Benjamin Lebwohl - USA (Moderator)
  • Unfolding story of celiac disease risk factors Benjamin Lebwohl - USA
  • PreventCD update Maria Luisa Mearin - The Netherlands
  • Results of a prospective study on infant nutrition and risk of celiac disease Carlo Catassi - Italy
  • Pregnancy and child outcomes in celiac disease Jonas Ludvigsson - Sweden
  •  
  • Important issues  Markku Maki - Finland (Moderator)
  • Screening in celiac disease in childhood, pros & cons Ivor Hill & Edwin Liu - USA
  • Gluten and biopsy outcome, why is it important in drug trials? Markku Maki - Finland

  • What is the status of the therapies? Joseph A. Murray, MD Mayo Clinic, USA (Moderator)
  • Drug development in celiac disease: FDA perspective Jessica Lee - United States Food & Drug Administration, USA
  • Measuring outcomes in celiac disease Daniel Leffler - USA
  • Glutenase therapy for celiac disease Daniel C. Adelman, MDAlvine Pharmaceuticals, Inc., USA
  • Larazotide : an update Joseph Murray - USA
  • Is a vaccine feasible for celiac disease?  Robert P. Anderson, BMedSc, MBChB, PhDImmusanT, Inc., USA
  • BL-7010 A therapy for celiac disease Yotam Nisemblat - Israel
  • Montelukast in celiac disease Sonia Kupfer - USA
  •  Development of tissue transglutaminase inhibitors Thomas DiRaimondo - USA

  • What is the status of the therapies?    Katri Kaukinen - Finland (Moderator)
  • Probiotics, do they have any role of celiac disease management?  Julio Bai - Argentina
  • Elafin, what is its role in celiac disease  Elena Verdu - Canada
  • Glutenase therapy (DSM)  Chris Mulder - The Netherlands
  • Gluten detection in the food chain  Jennifer Sealey-Voyksner - USA
  • The development of a gluten-degrading enzyme  Ingrid Swanson Pultz - USA

Speakers

  • Daniel C. Adelman, MD Alvine Pharmaceuticals, Inc., USA
  • Armin Alaedini, PhD Columbia University Medical Center, USA
  • Robert P. Anderson, BMedSc, MBChB, PhD ImmusanT, Inc., USA
  • Carolina Arguelles Grande, MD Columbia University Medical Center, USA
  • Julio C. Bai, MD Hospital de Gastroenterología Dr. Carlos Bonorino UdaondoArgentina
  • Govind Bhagat, MD Columbia University Medical Center, USA
  • Carlo Catassi, MD, MPH Università Politecnica delle Marche, Italy
  • Edward J. Ciaccio, PhD Columbia University Medical Center, USA
  • Paul Ciclitira, MD, PhD King's College London, UK
  • Amy R. DeFelice, MD Columbia University Medical Center, USA
  • Thomas R. DiRaimondo, PhD Sitari Pharma, Inc., USA
  • Alessio Fasano, MD Massachusetts General Hospital, USA
  • Daniel Getts, MBA, PhD Cour Pharmaceutical Development Co., USA
  • Peter H.R. Green, MD Columbia University Medical Center, USA
  • Marios Hadjivassiliou, MD Royal Hallamshire Hospital, UK
  • Ivor D. Hill, MD, MB Nationwide Children's Hospital, USA
  • Martin F. Kagnoff, MD University of California San Diego, USA
  • Donald Kasarda, PhD United States Department of Agriculture, USA
  • Katri Kaukinen, MD, PhD University of Tampere, Finland
  • Sonia Kupfer, MD University of Chicago, USA
  • Benjamin Lebwohl, MD, MS Columbia University Medical Center, USA
  • Jessica J. Lee, MD, MMSc United States Food and Drug Administration, USA
  • Daniel A. Leffler, MD, MS Beth Israel Deaconess Medical Center, USA
  • Suzanne K. Lewis, MD Columbia University Medical Center, USA
  • Edwin Liu, MD University of Colorado Denver, USA
  • Jonas F. Ludvigsson, MD, PhD Karolinska Institutet, Sweden
  • Knut E.A. Lundin, MD, PhD University of Oslo, Norway
  • Markku Maki, MD, PhD University of Tampere, Finland
  • Maria Luisa Mearin, MD Leiden University Medical Centre, The Netherlands
  • Joachim W. Messing, PhD Rutgers University, USA
  • Chris J.J. Mulder, MD, PhD VU University Medical Center, The Netherlands
  • Joseph A. Murray, MD Mayo Clinic, USA
  • Yotam Nisemblat, MSc, MBA BioLineRx Ltd., Israel
  • Ingrid Swanson Pultz, PhD University of Washington, USA
  • Norelle Rizkalla Reilly, MD Columbia University Medical Center, USA
  • Detlef Schuppan, MD, PhD Mainz University Medical Center, Germany
  • Jennifer A. Sealey Voyksner, PhD Immunogenics, LLC, USA
  • Ludvig M. Sollid, MD, PhD Oslo University Hospital, Norway
  • Reidun B. Stenberg, MD, PhD Orebro Universitet, Sweden
  • Elena Verdú, MD, PhD McMaster University, Canada
  • Alain Vicari, DVM, PhD Calypso Biotech SA, Switzerland
  • Robert H. Yolken, MD The Johns Hopkins University School of Medicine, USA